Oculis.png
Oculis and EURETINA Announces the Ramin Tadayoni Award
27 juin 2024 06h30 HE | Oculis Holding AG
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...
Oculis kynnir jákvæð
Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð
10 juin 2024 05h00 HE | Oculis Holding AG
ZUG, Sviss, June 10, 2024 (GLOBE NEWSWIRE) -- Virkni lyfsins var greinileg með bætingu á mörgum teiknum (e. signs) augnþurrks í öllum rannsóknarhópnum ásamt því sem aukin áhrif sáust hjá hópi...
Figure 1 - RELIEF Topline Results PR
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
10 juin 2024 05h00 HE | Oculis Holding AG
ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1...
Rapid & Favorable Response
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
10 juin 2024 05h00 HE | Oculis Holding AG
Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior...
Oculis logo.png
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
04 juin 2024 13h47 HE | Oculis Holding AG
ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity...
Oculis logo.png
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30 mai 2024 04h00 HE | Oculis Holding AG
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D....
Oculis birtir niðurs
Oculis birtir niðurstöður aðalfundar 2024 og tilkynnir um skipanir í stjórn og vísindaráð
30 mai 2024 04h00 HE | Oculis Holding AG
ZUG, Sviss, May 30, 2024 (GLOBE NEWSWIRE) -- Hluthafar samþykktu alla dagskrárliði og tillögur stjórnarRobert K. Warner M.B.A. og Arshad M. Khanani M.D. M.A. FASRS kjörnir í stjórnBaruch D....
Oculis Publishes Res
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30 mai 2024 04h00 HE | Oculis Holding AG
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) --Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS...
Oculis logo.png
Oculis updates share capital for its existing at-the-market offering program
17 mai 2024 16h30 HE | Oculis Holding AG
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the...
Oculis logo.png
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08 mai 2024 16h10 HE | Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...